NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.74 (+5.86%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.62
Bid12.65 x 800
Ask14.35 x 800
Day's Range12.72 - 13.56
52 Week Range12.30 - 53.70
Avg. Volume130,886
Market Cap317.591M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.50
Trade prices are not sourced from all markets
  • AVROBIO Enters Oversold Territory
    Zacks3 days ago

    AVROBIO Enters Oversold Territory

    AVROBIO, Inc. (AVRO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire3 days ago

    AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

    The Phase 1/2 clinical trial is a planned investigator-sponsored trial to be conducted by the University of California, San Diego (UCSD) under the direction of Stephanie Cherqui, PhD, Associate Professor in the Department of Pediatrics at UCSD and a leading expert in stem cells and gene therapy for cystinosis.

  • GlobeNewswire4 days ago

    AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019

    CAMBRIDGE, Mass., Jan. 17, 2019 -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates.

  • GlobeNewswire14 days ago

    AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

    Dr. Vickers brings a wealth of global pharmaceutical and biotechnology expertise to AVROBIO, with more than 25 years’ experience in the development and approval of innovative biologics and small molecules to treat diseases in a wide range of therapeutic areas. The Company also announced that Scott Requadt is transitioning off AVROBIO’s board to become CEO of a Blackstone portfolio company. “Phil is a great addition to our Board,” said Geoff MacKay, President and CEO of AVROBIO.

  • GlobeNewswirelast month

    AVROBIO, Inc. Added to NASDAQ Biotechnology Index

    AVROBIO, Inc. (AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company,  today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis.

  • Should You Avoid AVROBIO, Inc. (AVRO)?
    Insider Monkeylast month

    Should You Avoid AVROBIO, Inc. (AVRO)?

    Is AVROBIO, Inc. (NASDAQ:AVRO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]

  • GlobeNewswirelast month

    AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease

    AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-01, for the treatment of Fabry disease. The gene therapy consists of the patient’s own hematopoietic stem cells transduced with AVROBIO’s lentiviral vector, carrying a functional version of the GLA gene that encodes α‑galactosidase A (AGA) – the enzyme that is deficient in Fabry disease.

  • GlobeNewswirelast month

    AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Dec. 18, 2018 -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock.

  • GlobeNewswirelast month

    AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires

    Three of them, Birgitte Volck, M.D., Ph.D., President of Research and Development, Erik Ostrowski, Chief Financial Officer, and Steven Avruch, General Counsel, will report to AVROBIO’s President and CEO, Geoff MacKay. The fourth, Josie Yang, Ph.D., Vice President and Head of Regulatory Affairs, will report to Dr. Volck.

  • Benzinga2 months ago

    Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

    With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week.  The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...

  • GlobeNewswire2 months ago

    AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update

    “The third quarter has been productive for AVROBIO,” commented Geoff MacKay, President and Chief Executive Officer of AVROBIO. “In a recent clinical data update on AVR-RD-01, we were pleased with the α‑galactosidase A (AGA) enzyme activity demonstrated in patients with Fabry disease. In addition, we have achieved our first regulatory milestone for our gene therapy for Gaucher disease as it advances towards the clinic.

  • Benzinga6 months ago

    Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls

    Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...

  • 8 Biotech Stocks With IPOs This Week
    InvestorPlace7 months ago

    8 Biotech Stocks With IPOs This Week

    This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.